[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55815A - Traitement de céphalées à l'aide d'anticorps anti-cgrp - Google Patents

Traitement de céphalées à l'aide d'anticorps anti-cgrp

Info

Publication number
MA55815A
MA55815A MA055815A MA55815A MA55815A MA 55815 A MA55815 A MA 55815A MA 055815 A MA055815 A MA 055815A MA 55815 A MA55815 A MA 55815A MA 55815 A MA55815 A MA 55815A
Authority
MA
Morocco
Prior art keywords
headaches
treatment
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
MA055815A
Other languages
English (en)
Inventor
Roger K Cady
Joseph Hirman
Lahar Mehta
Barbara Schaeffler
Jeffrey T L Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/fr
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA55815A publication Critical patent/MA55815A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055815A 2019-05-02 2020-02-18 Traitement de céphalées à l'aide d'anticorps anti-cgrp MA55815A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (fr) 2019-01-08 2020-01-08 Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp

Publications (1)

Publication Number Publication Date
MA55815A true MA55815A (fr) 2022-03-09

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055815A MA55815A (fr) 2019-05-02 2020-02-18 Traitement de céphalées à l'aide d'anticorps anti-cgrp

Country Status (17)

Country Link
US (1) US20220251178A1 (fr)
EP (1) EP3962522A4 (fr)
JP (1) JP2022533030A (fr)
KR (1) KR20220004053A (fr)
CN (1) CN113811326A (fr)
AU (1) AU2020267107A1 (fr)
BR (1) BR112020027063A2 (fr)
CA (1) CA3133571A1 (fr)
CL (1) CL2021002866A1 (fr)
DO (1) DOP2021000215A (fr)
EA (1) EA202192865A1 (fr)
IL (1) IL287759A (fr)
JO (1) JOP20210247A1 (fr)
MA (1) MA55815A (fr)
MX (1) MX2021013426A (fr)
SG (1) SG11202110637RA (fr)
WO (1) WO2020222892A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023026245A1 (fr) * 2021-08-27 2023-03-02 H. Lundbeck A/S Traitement de la céphalée vasculaire de horton à l'aide d'anticorps anti-cgrp
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3495392T (pt) * 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
JP6374789B2 (ja) * 2011-05-20 2018-08-15 アルダーバイオ・ホールディングズ・エルエルシー 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
IL247853B (en) * 2014-03-21 2022-08-01 Teva Pharmaceuticals Int Gmbh Antibodies which are antagonists against a peptide relating to the calcitonin gene and methods of using them
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017186928A1 (fr) * 2016-04-29 2017-11-02 Curevac Ag Arn codant pour un anticorps
JP6937368B2 (ja) * 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
PE20211707A1 (es) * 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp

Also Published As

Publication number Publication date
CL2021002866A1 (es) 2022-06-17
CA3133571A1 (fr) 2020-11-05
BR112020027063A2 (pt) 2021-11-16
IL287759A (en) 2022-01-01
CN113811326A (zh) 2021-12-17
EA202192865A1 (ru) 2022-02-14
US20220251178A1 (en) 2022-08-11
DOP2021000215A (es) 2021-11-21
SG11202110637RA (en) 2021-10-28
EP3962522A4 (fr) 2023-07-19
WO2020222892A1 (fr) 2020-11-05
KR20220004053A (ko) 2022-01-11
EP3962522A1 (fr) 2022-03-09
AU2020267107A1 (en) 2021-10-07
JP2022533030A (ja) 2022-07-21
MX2021013426A (es) 2021-12-10
JOP20210247A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
MA54704A (fr) Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA54709A (fr) Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
EA201791590A1 (ru) Антитела к tau и их применение
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
MA55815A (fr) Traitement de céphalées à l'aide d'anticorps anti-cgrp
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
MA54052A (fr) Formulation d'anticorps
MA55720A (fr) Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer